Company Profile:

In 1968, IMS began business with the launch of unit dose emergency drugs. Over the years, the company continued its growth through the licensing of their products to major manufacturers of drugs and health care products.

In 1998, Amphastar acquired IMS from Medeva, PLC, a London based pharmaceutical company. Under Amphastar's management, IMS experienced tremendous growth in research and development.

IMS is a federally registered and internationally licensed manufacturer of sterile injectable pharmaceuticals supplying both domestic and international markets. These sterile injectables are used with a wide variety of IMS delivery systems, including prefilled syringes and vials.

IMS maintains an excellent regulatory/cGMP compliance record and has a wealth of experience in dealing with Federal, international and   local regulatory agencies. Our facilities are registered and inspected regularly by the United States Food and Drug Administration (FDA), the Medicines and Healthcare Products Regulatory Agency (MHRA), the United States Drug Enforcement Agency (DEA), and the California State Food and Drug Board.